Missing content? – Request curation!
Request curation for specific Genes, Variants, or PubMed publications.
Have questions, comments, or suggestions? - Let us know!
Email us at : ckbsupport@jax.org
Therapy Name | Defactinib + Letrozole + RO5126766 |
Synonyms | |
Therapy Description | |
Drug Name | Trade Name | Synonyms | Drug Classes | Drug Description |
---|---|---|---|---|
Defactinib | VS-6063|PF-04554878 | FAK inhibitor 15 | Defactinib (VS-6063) inhibits FAK, resulting in decreased downstream signaling, and potentially leading to reduced tumor cell proliferation and survival (PMID: 31739184). | |
Letrozole | Femara | Letrozol | Aromatase Inhibitor 3 | Femara (letrozole) is an aromatase inhibitor, which inhibits estrogen synthesis, and is approved for postmenopausal women with hormone receptor positive breast cancer (FDA.gov). |
RO5126766 | Avutometinib|VS-6766|VS6766|VS 6766|CH5126766|CH-5126766|R-7304|RG-7304 | MEK inhibitor (Pan) 26 MEK1 Inhibitor 26 MEK2 Inhibitor 24 RAF Inhibitor (Pan) 28 | RO5126766 (VS-6766) is a RAF/MEK inhibitor, which potentially leads to decreased tumor cell growth and inhibition of tumor growth (PMID: 34288272). |
Molecular Profile | Indication/Tumor Type | Response Type | Therapy Name | Approval Status | Evidence Type | Efficacy Evidence | References |
---|
Clinical Trial | Phase | Therapies | Title | Recruitment Status | Covered Countries | Other Countries |
---|---|---|---|---|---|---|
NCT06394804 | Phase II | Defactinib + Letrozole + RO5126766 | A Study of Avutometinib, Defactinib, and Letrozole in People With Low-Grade Serous Ovarian Cancer (CHAMELEON) | Recruiting | USA | 0 |